Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124117) titled 'A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: OBI Pharma, Inc
Condition:
Advanced Solid Tumor
Intervention:
Drug: OBI-902
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 11, 2025
Target Sample Size: 111
Countries of Recruitment:
United States
Taiwan
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07124117
Published b...